Lyudmila Bazhenova, MD, explains why the updated taletrectinib label does not change her practice and reviews new WCLC subgroup data in ROS1+ NSCLC.
|Videos|June 7, 2016
Emerging Agents for T790M-Mutant Patients With NSCLC
Author(s)Howard L. (Jack) West, MD
Howard L. (Jack) West, MD, medical oncologist, director, Thoracic Oncology Program, Swedish Cancer Institute, discusses emerging agents on the horizon for patients with T790M-mutant patients with non-small cell lung cancer.
Advertisement
Newsletter
Stay up to date on practice-changing data in community practice.
SubscribeAdvertisement
Related to this article
Firmonertinib did not improve PFS in the phase 3 FURVENT trial in patients with EGFR exon 20 insertion–mutant NSCLC.
Submission of a new drug application for zipalertinib plus chemotherapy has begun under the FDA's RTOR program, based on phase 3 REZILIENT3 data showing a 6-month PFS gain.
Theodore Wagener, PhD, of Ohio State discusses the design of the phase 2 DREAM LUNG study of psilocybin-assisted therapy for depression in non–small cell lung cancer.
FDA grants 2 breakthrough therapy designations to Temab-A, speeding development for hard-to-treat colorectal cancer and c-Met–expressing lung cancer.
TRE-515 could improve the durability of response in combination with KRAS inhibition in patients with advanced non–small cell lung cancer, investigators stated.
Five myeloma experts share their top takeaways from IMS 2026, including the CERVINO trial and long-term follow-up from the PERSEUS study.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
CLL Treatment Enters a New Era of Targeted Combinations
2
Psilocybin-Assisted Therapy Aims at Existential Distress in Lung Cancer
3
SurVaxM Improves OS Only in Younger Subgroup in Newly Diagnosed Glioblastoma
4
AI in Precision Oncology: A Paradigm Shift
5